Depatuxizumab

N/A

Report date: 2022/07/04 19:38:02

Base Information

Drug NameDepatuxizumab
Drug Alias NamemAb-806ch806ABT-806
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Chimeric monoclonal antibodyBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanized
Mechanisms of ActionEpidermal growth factor receptor erbB1 antagonists
TargetsEpidermal growth factor receptor erbB1
Therapy Area/IndicationsSolid tumoursNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesAustralia
CombinationsNo
Global Highest StatusPending (Phase 1 Clinical)
Highest Status in ChinaN/A
Originator CompaniesLudwig Institute For Cancer Research
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesAbbott LaboratoriesLife Science PharmaceuticalsLudwig Institute For Cancer Research +[4] 
Active IndicationsN/A
Inactive IndicationsSolid tumoursNeoplasms

Other Information

ATC CodeN/A
Related LinksN/A